Results 271 to 278 of about 57,705 (278)

Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial

Lancet Oncology, The, 2013
Kwok-Leung Cheung, Andrew M Wardley, Anthony Howell, Howell A, Howell T   +2 more
exaly  

Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial

Lancet Oncology, The, 2019
Eleftherios P Mamounas, Jong-Hyeon Jeong, Adam M Brufsky   +2 more
exaly  

Randomized Trial of Denosumab in Patients Receiving Adjuvant Aromatase Inhibitors for Nonmetastatic Breast Cancer

Journal of Clinical Oncology, 2008
Rowan T Chlebowski
exaly  

Aromatase Inhibitors as Adjuvant Therapy for Postmenopausal Patients With Early Stage Breast Cancer

Ca-A Cancer Journal for Clinicians, 2005
exaly  

Extended adjuvant aromatase inhibition after sequential endocrine therapy (DATA): a randomised, phase 3 trial

Lancet Oncology, The, 2017
Irene E G Van Hellemond, Judith R Kroep, Sabine C Linn   +2 more
exaly  

SWITCH TO AROMATASE INHIBITOR BETTER THAN CONTINUING TAMOXIFEN

Ca-A Cancer Journal for Clinicians, 2005
exaly  

Aromatase Inhibitors in Breast Cancer

New England Journal of Medicine, 2003
Mitch Dowsett
exaly  

Biological determinants of endocrine resistance in breast cancer

Nature Reviews Cancer, 2009
exaly